PL3652145T3 - Krystaliczna postać tetrachlorowodorku trietylenotetraaminy i jej zastosowanie farmaceutyczne - Google Patents

Krystaliczna postać tetrachlorowodorku trietylenotetraaminy i jej zastosowanie farmaceutyczne

Info

Publication number
PL3652145T3
PL3652145T3 PL19724752.1T PL19724752T PL3652145T3 PL 3652145 T3 PL3652145 T3 PL 3652145T3 PL 19724752 T PL19724752 T PL 19724752T PL 3652145 T3 PL3652145 T3 PL 3652145T3
Authority
PL
Poland
Prior art keywords
crystalline form
pharmaceutical use
triethylenetetramine tetrahydrochloride
tetrahydrochloride
triethylenetetramine
Prior art date
Application number
PL19724752.1T
Other languages
English (en)
Inventor
Timothy James Morley
Ronnie Maxwell Lawrence
Naseem AMIN
Original Assignee
Orphalan S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62455418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3652145(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orphalan S.A. filed Critical Orphalan S.A.
Publication of PL3652145T3 publication Critical patent/PL3652145T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82Purification; Separation; Stabilisation; Use of additives
    • C07C209/84Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL19724752.1T 2018-05-04 2019-05-03 Krystaliczna postać tetrachlorowodorku trietylenotetraaminy i jej zastosowanie farmaceutyczne PL3652145T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18290048 2018-05-04
PCT/EP2019/061441 WO2019211464A1 (en) 2018-05-04 2019-05-03 Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

Publications (1)

Publication Number Publication Date
PL3652145T3 true PL3652145T3 (pl) 2025-12-22

Family

ID=62455418

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19724752.1T PL3652145T3 (pl) 2018-05-04 2019-05-03 Krystaliczna postać tetrachlorowodorku trietylenotetraaminy i jej zastosowanie farmaceutyczne

Country Status (24)

Country Link
US (7) US10988436B2 (pl)
EP (2) EP4613337A3 (pl)
JP (2) JP7679294B2 (pl)
KR (2) KR102843554B1 (pl)
CN (3) CN119306616A (pl)
AR (1) AR115080A1 (pl)
AU (2) AU2019263969B2 (pl)
CA (1) CA3096423A1 (pl)
CO (1) CO2020013806A2 (pl)
DE (1) DE19724752T1 (pl)
DK (1) DK3652145T3 (pl)
EA (1) EA202092241A1 (pl)
ES (1) ES2769049T3 (pl)
FI (1) FI3652145T3 (pl)
HR (1) HRP20251307T1 (pl)
MA (2) MA51919A1 (pl)
PL (1) PL3652145T3 (pl)
PT (1) PT3652145T (pl)
RS (1) RS67287B1 (pl)
SA (1) SA520420467B1 (pl)
SG (1) SG11202010785UA (pl)
SI (1) SI3652145T1 (pl)
SM (1) SMT202500387T1 (pl)
WO (1) WO2019211464A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202500387T1 (it) 2018-05-04 2025-11-10 Orphalan S A Forma cristallina del tetraidrocloruro di trietilenetetrammina e suo uso farmaceutico
KR102489293B1 (ko) * 2020-10-15 2023-01-17 (주) 에프엔지리서치 공업용 등급의 트리에틸렌테트라민의 고순도 정제 방법
US20240382435A1 (en) 2021-04-26 2024-11-21 Orphalan S.A. Non-ceruloplasmin bound copper level monitoring
CN116675607A (zh) * 2022-02-23 2023-09-01 裕捷股份有限公司 一种三亚乙基四胺四氢氯化物及其制备方法与组合物
TWI819502B (zh) 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物
WO2024018394A1 (en) * 2022-07-19 2024-01-25 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form a of n, n'-bis(2-aminoethyl)-1,2-ethanediamine tetrahydrochloride
EP4487839A1 (en) 2023-07-03 2025-01-08 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical dosage form comprising trientine tetrahydrochloride, and method for preparing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1078731A (en) 1976-12-16 1980-06-03 Charles E. Frosst And Co. Skeletal imaging kit utilizing triethylene tetramine hexa (methylene phosphonic acid)
CS197093B1 (cs) * 1978-06-16 1980-04-30 Ivo Kuhr Způsob přípravy čistého dihydrochloridu triethylentetraminu
DE19724752A1 (de) 1997-04-24 1998-11-05 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von Entzündungen und Wunden der Haut
AU3133399A (en) 1998-04-03 1999-10-25 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
JP4369003B2 (ja) 2000-02-23 2009-11-18 ハリマ化成株式会社 ハンダ付け用フラックス
WO2003075910A1 (en) 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
ATE555782T1 (de) 2002-03-08 2012-05-15 Philera New Zealand Ltd Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
AU2003214725A1 (en) 2002-08-20 2004-03-11 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
NZ545724A (en) 2003-03-18 2007-11-30 Protemix Corp Ltd Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
CA2577634C (en) 2004-07-19 2015-07-07 Protemix Corporation Limited Synthesis of triethylenetetramines
CN105753719B (zh) * 2014-12-17 2019-06-21 四川科瑞德凯华制药有限公司 一种盐酸曲恩汀化合物
JP6326477B2 (ja) 2015-12-25 2018-05-16 三洋化成工業株式会社 高分子凝集剤
SMT202500387T1 (it) * 2018-05-04 2025-11-10 Orphalan S A Forma cristallina del tetraidrocloruro di trietilenetetrammina e suo uso farmaceutico
WO2020006027A1 (en) 2018-06-29 2020-01-02 Sharp Laboratories Of America, Inc. Ultra-reliability design for physical uplink control channel (pucch) in 5th generation (5g) new radio (nr)
WO2020019211A1 (zh) 2018-07-25 2020-01-30 北京小米移动软件有限公司 Mtc系统的随机接入方法、装置及存储介质
TWI819502B (zh) 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物

Also Published As

Publication number Publication date
US20200392068A1 (en) 2020-12-17
SI3652145T1 (sl) 2025-12-31
ES2769049T3 (en) 2025-11-21
US20220169594A1 (en) 2022-06-02
US20210188761A1 (en) 2021-06-24
AU2024227767A1 (en) 2024-11-21
MA51919A1 (fr) 2021-11-30
AU2019263969B2 (en) 2024-08-01
CN111479798B (zh) 2024-11-01
CN119306616A (zh) 2025-01-14
EP3652145B1 (en) 2025-09-17
ES2769049T1 (es) 2020-06-24
CN111479798A (zh) 2020-07-31
US12358861B2 (en) 2025-07-15
DE19724752T1 (de) 2020-07-09
EP4613337A2 (en) 2025-09-10
CN114394904A (zh) 2022-04-26
TW202002956A (zh) 2020-01-16
KR102843554B1 (ko) 2025-08-08
PT3652145T (pt) 2025-09-29
BR112020018451A2 (pt) 2020-12-29
US12358862B2 (en) 2025-07-15
AU2019263969A1 (en) 2020-10-22
JP7679294B2 (ja) 2025-05-19
JP2025037978A (ja) 2025-03-18
US10988436B2 (en) 2021-04-27
HRP20251307T1 (hr) 2025-12-05
CO2020013806A2 (es) 2021-01-29
FI3652145T3 (fi) 2025-10-22
EA202092241A1 (ru) 2021-04-01
KR20250121158A (ko) 2025-08-11
MA58726A1 (fr) 2023-09-27
US11117855B2 (en) 2021-09-14
US20240360071A1 (en) 2024-10-31
AR115080A1 (es) 2020-11-25
RS67287B1 (sr) 2025-11-28
EP3652145A1 (en) 2020-05-20
US20250074862A1 (en) 2025-03-06
EP4613337A3 (en) 2025-09-17
CA3096423A1 (en) 2019-11-07
JP2021531322A (ja) 2021-11-18
US20210163398A1 (en) 2021-06-03
SG11202010785UA (en) 2020-11-27
KR20210005270A (ko) 2021-01-13
SMT202500387T1 (it) 2025-11-10
DK3652145T3 (da) 2025-10-20
US11072577B2 (en) 2021-07-27
NZ768613A (en) 2025-06-27
SA520420467B1 (ar) 2024-04-28
MA58726B1 (fr) 2025-02-28
US20250382257A1 (en) 2025-12-18
WO2019211464A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
SG11202010785UA (en) Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
IL279464A (en) Pharmaceutical formulation of odevixibat
SG10202111997YA (en) Sustainable construction material and method of preparation and use thereof
IL290745A (en) A pyrimidine compound and its pharmaceutical use
IL283782A (en) Analosomes and methods of use
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL272108A (en) New crystal structures of vilanterol tripentate and processes for their preparation
IL264403A (en) Vortioxetine analogue and use and preparation thereof
HUE062956T2 (hu) Eljárások niraparib és köztitermékei elõállítására
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
IL274701A (en) Promote drugs, compositions and methods of their use
ZA201906326B (en) Analogs of deutetrabenazine, their preparation and use
ZA202008034B (en) Ivosidenib forms and pharmaceutical compositions
IL278294A (en) HSV-2-DELTA-gD compositions and methods for their production and use
IL275655A (en) A process for the preparation of amino-pyrimidine and its intermediates
SG11202103533UA (en) Alkoxybenzaldehyde derivatives and precursors thereof
IL272837A (en) A process for preparing tubolysins and their intermediates
ZA201908264B (en) Formulations of homotaurines and salts thereof
PL3621941T3 (pl) Zastosowanie prekursorów do wytwarzania aminokwasów znakowanych węglem 11C oraz ich pochodnych
GB201810326D0 (en) Crystalline form of sacubitril, its preparation and use
HUP1800397A2 (en) Process for the preparation of lumateperone and salts thereof
EP3889157C0 (en) SALT AND CRYSTALLINE FORM OF A FUROPYRIMIDINE COMPOUND AND THEIR PHARMACEUTICAL USE
PL3868768T3 (pl) Farmaceutyczny kryształ kontezolidu acefosamilu, sposób jego wytwarzania i jego zastosowania
GB201814520D0 (en) New pharmaceutical use